Payment overview · 2025
General Payments
$1,190.04
77 reported records · 19 companies
Healthcare provider profile · identity verified
Adam Novack, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAVANNAH, GA · NPI 1265699433
Verified facts
What the public records show
CMS Open Payments records show Adam Novack, M.D. received $1,190.04 in general payments during 2025 across 77 reported records.
Novo Nordisk Inc accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.83 | 16.2% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.72 | 12.5% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $106.20 | 8.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.11 | 8.7% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $99.01 | 8.3% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.34 | 6.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.62 | 6.2% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $62.99 | 5.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.64 | 5.0% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.04 | 3.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.01 | 3.8% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $30.45 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.76 | 2.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.96 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.17 | 1.7% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.55 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.18 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.12 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.34 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,190.04 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.57 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $139.72 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.72 | 16 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $134.03 | 11 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $106.20 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $99.01 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.60 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.22 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.63 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.26 | 3 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $35.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $30.45 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 186 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 150 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 208 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
186 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
208 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
186 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 918 | 263 |
| Amlodipine Besylate | Amlodipine Besylate | 783 | 235 |
| Atorvastatin Calcium | Atorvastatin Calcium | 681 | 202 |
| Losartan Potassium | Losartan Potassium | 557 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 145 |
| Omeprazole | Omeprazole | 399 | 126 |
| Telmisartan | Telmisartan | 369 | 102 |
| Carvedilol | Carvedilol | 347 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 336 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 94 |
| Lisinopril | Lisinopril | 249 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 243 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 81 |
| Metformin Hcl | Metformin Hcl | 237 | 69 |
| Ezetimibe | Ezetimibe | 226 | 69 |
| Tramadol Hcl | Tramadol Hcl | 225 | 61 |
| Gabapentin | Gabapentin | 219 | 69 |
| Ozempic | Semaglutide | 208 | 36 |
| Simvastatin | Simvastatin | 202 | 57 |
| Alprazolam | Alprazolam | 198 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 52 |
| Januvia | Sitagliptin Phosphate | 195 | 48 |
| Metformin Hcl Er | Metformin Hcl | 187 | 56 |
| Eliquis | Apixaban | 186 | 42 |
| Furosemide | Furosemide | 179 | 63 |
| Fluoxetine Hcl | Fluoxetine Hcl | 178 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 53 |
| Potassium Chloride | Potassium Chloride | 163 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 49 |
| Jardiance | Empagliflozin | 150 | 40 |
| Trazodone Hcl | Trazodone Hcl | 145 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 45 |
| Allopurinol | Allopurinol | 142 | 43 |
| Glimepiride | Glimepiride | 141 | 45 |
| Meloxicam | Meloxicam | 137 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 41 |
| Chlorthalidone | Chlorthalidone | 128 | 38 |
| Celecoxib | Celecoxib | 125 | 32 |
| Montelukast Sodium | Montelukast Sodium | 120 | 33 |
| Fenofibrate | Fenofibrate,micronized | 114 | 33 |
| Lorazepam | Lorazepam | 106 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 28 |
| Sertraline Hcl | Sertraline Hcl | 104 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 32 |
| Farxiga | Dapagliflozin Propanediol | 101 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 35 |
| Mounjaro | Tirzepatide | 96 | 16 |
| Alendronate Sodium | Alendronate Sodium | 95 | 31 |
| Donepezil Hcl | Donepezil Hcl | 95 | 27 |
| Clonazepam | Clonazepam | 93 | 20 |
| Azithromycin | Azithromycin | 90 | 83 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 25 |
| Bupropion Xl | Bupropion Hcl | 81 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 18 |
| Spironolactone | Spironolactone | 76 | 28 |
| Finasteride | Finasteride | 74 | 19 |
| Famotidine | Famotidine | 73 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 20 |
| Gemfibrozil | Gemfibrozil | 71 | 21 |
| Synthroid | Levothyroxine Sodium | 63 | 15 |
| Diazepam | Diazepam | 61 | suppressed |
| Atenolol | Atenolol | 58 | 18 |
| Dutasteride | Dutasteride | 56 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 18 |
| Novolog Flexpen | Insulin Aspart | 53 | 14 |
| Bumetanide | Bumetanide | 50 | 16 |
| Rybelsus | Semaglutide | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Eszopiclone | Eszopiclone | 49 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 30 |
| Ondansetron Odt | Ondansetron | 48 | 26 |
| Sildenafil Citrate | Sildenafil Citrate | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 14 |
| Lansoprazole | Lansoprazole | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 45 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 21 |
| Buspirone Hcl | Buspirone Hcl | 40 | 16 |
| Prednisone | Prednisone | 40 | 29 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Valsartan | Valsartan | 39 | 12 |
| Fluconazole | Fluconazole | 38 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 28 |
| Estradiol | Estradiol | 30 | 12 |
| Gemtesa | Vibegron | 30 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 25 |
| Nystatin | Nystatin | 27 | 16 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Baclofen | Baclofen | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Torsemide | Torsemide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prevalite | Cholestyramine | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,190.04 · 77 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAMZYOS, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FUROSCIX, JARDIANCE, LEQVIO, LOKELMA, MOUNJARO, OPSUMIT, OPSYNVI, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Tyvaso, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error